Nanobiotix (NBTX) Competitors $4.75 -0.12 (-2.55%) As of 03:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. LENZ, CRMD, OCS, RCUS, AVXL, COGT, CMRX, CDMO, AVBP, and SNDXShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include LENZ Therapeutics (LENZ), CorMedix (CRMD), Oculis (OCS), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors LENZ Therapeutics CorMedix Oculis Arcus Biosciences Anavex Life Sciences Cogent Biosciences Chimerix Avid Bioservices ArriVent BioPharma Syndax Pharmaceuticals LENZ Therapeutics (NASDAQ:LENZ) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings. Does the media refer more to LENZ or NBTX? In the previous week, LENZ Therapeutics had 2 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for LENZ Therapeutics and 1 mentions for Nanobiotix. LENZ Therapeutics' average media sentiment score of 0.93 beat Nanobiotix's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in LENZ or NBTX? 54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts recommend LENZ or NBTX? LENZ Therapeutics presently has a consensus price target of $46.60, indicating a potential upside of 48.03%. Nanobiotix has a consensus price target of $8.00, indicating a potential upside of 68.56%. Given Nanobiotix's higher possible upside, analysts plainly believe Nanobiotix is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is LENZ or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -23.74% -22.65% Nanobiotix N/A N/A N/A Which has preferable earnings and valuation, LENZ or NBTX? LENZ Therapeutics has higher earnings, but lower revenue than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.77-17.79Nanobiotix$39.18M5.71-$73.73MN/AN/A Which has more risk & volatility, LENZ or NBTX? LENZ Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. SummaryLENZ Therapeutics beats Nanobiotix on 9 of the 13 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.54M$2.43B$5.53B$9.03BDividend YieldN/A1.78%5.24%4.01%P/E RatioN/A3.8319.3119.89Price / Sales5.71644.76424.59117.07Price / CashN/A21.7726.2128.59Price / Book-3.144.497.925.55Net Income-$73.73M$31.26M$3.17B$248.49M7 Day Performance0.34%1.60%2.18%5.37%1 Month Performance0.76%2.46%1.25%6.63%1 Year Performance-13.08%-0.33%33.90%21.20% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix1.6687 of 5 stars$4.75-2.5%$8.00+68.6%-8.2%$229.54M$39.18M0.00100News CoveragePositive NewsGap UpLENZLENZ Therapeutics1.3272 of 5 stars$29.31-2.9%$46.60+59.0%+80.2%$849.45MN/A-16.56110CRMDCorMedix2.5699 of 5 stars$12.32-1.4%$17.14+39.1%+182.5%$847.81M$43.47M56.0030High Trading VolumeOCSOculis1.7204 of 5 stars$19.41+0.3%$35.33+82.0%+62.6%$844.87M$780K-7.352RCUSArcus Biosciences2.7601 of 5 stars$8.17+2.8%$21.29+160.5%-40.0%$841.79M$258M-1.95500AVXLAnavex Life Sciences3.567 of 5 stars$9.22-2.7%$44.00+377.2%+155.8%$809.33MN/A-16.7640COGTCogent Biosciences2.5888 of 5 stars$7.18+1.1%$14.43+101.0%-9.8%$808.38MN/A-3.9080Trending NewsAnalyst ForecastOptions VolumeGap UpTrading HaltedCMRXChimerix0.6253 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6863 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeAVBPArriVent BioPharma1.7212 of 5 stars$21.77-5.0%$40.00+83.7%+11.6%$783.81MN/A-5.7740SNDXSyndax Pharmaceuticals3.127 of 5 stars$9.36+3.5%$35.80+282.5%-55.7%$777.87M$23.68M-2.42110 Related Companies and Tools Related Companies LENZ Therapeutics Competitors CorMedix Competitors Oculis Competitors Arcus Biosciences Competitors Anavex Life Sciences Competitors Cogent Biosciences Competitors Chimerix Competitors Avid Bioservices Competitors ArriVent BioPharma Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
